Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac

A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac Diclofenac is widely used to manage chronic inflammatory and degenerative joint diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and extra-articular rheumatism. Its various mechanisms of action make it particularly effective in treating nociceptive pain, but it is also an alternative for treating spinal and chronic central pain. Osteoarthritis and rheumatoid arthritis are the most frequently encountered arthritic conditions in adults. The management of nociceptive pain requires a sequential hierarchical approach, with the initial NSAID treatment being characterized by the replacement of one drug with another, or complete discontinuation usually because of insufficient pain control. OA- and RA-related pain is complex and multifactorial, and due to physiological interactions between the signaling of the central and peripheral nervous systems. The mechanisms of action of diclofenac make it particularly effective in treating both nociceptive pain and chronic central pain. This review underlines the mechanisms of diclofenac involved in chronic and acute joint pain, the most relevant adverse events. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pain and Therapy Springer Journals

A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac

Download PDF
15 pages

Loading next page...
 
/lp/springer_journal/a-review-of-chronic-musculoskeletal-pain-central-and-peripheral-EIT0XEhXBu
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Pain Medicine
ISSN
2193-8237
eISSN
2193-651X
DOI
10.1007/s40122-018-0100-2
Publisher site
See Article on Publisher Site

Abstract

Diclofenac is widely used to manage chronic inflammatory and degenerative joint diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and extra-articular rheumatism. Its various mechanisms of action make it particularly effective in treating nociceptive pain, but it is also an alternative for treating spinal and chronic central pain. Osteoarthritis and rheumatoid arthritis are the most frequently encountered arthritic conditions in adults. The management of nociceptive pain requires a sequential hierarchical approach, with the initial NSAID treatment being characterized by the replacement of one drug with another, or complete discontinuation usually because of insufficient pain control. OA- and RA-related pain is complex and multifactorial, and due to physiological interactions between the signaling of the central and peripheral nervous systems. The mechanisms of action of diclofenac make it particularly effective in treating both nociceptive pain and chronic central pain. This review underlines the mechanisms of diclofenac involved in chronic and acute joint pain, the most relevant adverse events.

Journal

Pain and Therapy – Springer Journals

Published: Jun 5, 2018

References

  • Single dose oral diclofenac for acute postoperative pain in adults
    Moore, RA; McQuay, HJ; Derry, P
  • Diclofenac: an update on its mechanism of action and safety profile
    Gan, TJ
  • Mechanism of action of anti-inflammatory drugs
    Vane, JR; Botting, RM
  • Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state
    Tegeder, I; Lotsch, J; Krebs, S
  • In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases
    Wittenberg, RH; Willburger, RE; Kleemeyer, KS
  • Effect of diclofenac sodium on the arachidonic acid cascade
    Ku, EC; Lee, W; Kothari, HV
  • Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen
    Giagoudakis, G; Markantonis, SL
  • Cyclooxygenase-independent actions of cyclooxygenase inhibitors
    Tegeder, I; Pfeilschifter, J; Geisslinger, G
  • Nonsteroid drug selectivities for cyclooxygenase- 1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
    Warner, TD; Giuliano, F; Vojnovic, I
  • Diversity of group types, regulation, and function of phospholipase A2
    Dennis, EA
  • Effect of phagocytosis and ionophores on release and metabolism of arachidonic acid from human neutrophils
    Walsh, CE; Dechatelet, LR; Thomas, MJ
  • An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac
    Kothari, HV; Lee, WH; Ku, EC
  • Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis
    Nevalainen, TJ; Gronroos, JM; Kortesuo, PT
  • Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro
    Makela, A; Kuusi, T; Schroder, T
  • Activation of human inflammatory cells by secreted phospholipases A2
    Triggiani, M; Granata, F; Frattini, A
  • Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7A° resolution
    Singh, N; Jabeen, T; Sharma, S
  • Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase
    Clish, CB; Sun, YP; Serhan, CN
  • Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization
    Tonussi, CR; Ferreira, SH
  • Effects of nitric oxide on glutamate-gated channels and other ionic channels
    Fagni, L; Bockaert, J
  • Role of ATP-sensitive Kþ channels in cGMP-mediated pial artery vasodilation
    Armstead, WM
  • Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(þ) channels in the rat PGE2-induced hyperalgesic paw
    Soares, AC; Duarte, ID
  • Diclofenac-induced peripheral antinociception is associated with ATP-sensitive Kþ channels activation
    Alves, DP; Tatsuo, MA; Leite, R
  • Peripheral nerve and diclofenac sodium: Molecular and clinical approaches
    Kaplan, AA; Yurt, KK; Deniz, ÖG; Altun, G
  • The mode of action of analgesic drugs in adjuvant arthritic rats as an experimental model of chronic inflammatory pain: possible central analgesic action of acidic nonsteroidal antiinflammatory drugs
    Okuyama, S; Aihara, H
  • Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations
    Sacerdote, P; Monza, G; Mantegazza, P
  • Localization of the central antinociceptive effects of diclofenac in the rat
    Bjorkman, RL; Hedner, T; Hallman, KM
  • Diclofenac increases beta-endorphin plasma concentrations
    Martini, A; Bondiolotti, GP; Sacerdote, P
  • Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-d-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat
    Bjorkman, R; Hallman, KM; Hedner, J
  • The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism
    Dong, X-D
  • Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling
    Adamson, DJ; Frew, D; Tatoud, R; Wolf, CR; Palmer, CN
  • Microglia: intrinsic immunoeffector cell of the brain
    Gehrmann, J; Matsumoto, Y; Kreutzeberg, GW
  • Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells
    Yamazaki, R; Kusunoki, N; Matsuzaki, T
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation
    Na, HK; Surh, YJ
  • Spinal anti-inflammatory action of diclofenac
    Sandri, A
  • Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines
    Ayoub, SS; Botting, RM; Joshi, AN
  • The role of substance P in inflammatory disease
    O’Connor, TM; O’Connell, J; O’Brien, DI
  • Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production
    Tsuboi, I; Tanaka, H; Nakao, M
  • In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators
    Henrotin, Y; Leval, X; Mathy-Hartet, M
  • Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery
    Mahdy, AM; Galley, HF; Abdel-Wahed, MA
  • Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac and naproxen
    Sacerdote, P; Carrabba, M; Galante, A
  • Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis
    Gonzalez, E; Cruz, C; Nicolas, R
  • Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid sensing ion channels in nociceptors
    Voilley, N; Weille, J; Mamet, J
  • Mechanisms of non-steroid anti-inflammatory drugs action on ASICs expressed in hippocampal interneurons
    Dorofeeva, NA; Barygin, OI; Staruschenko, A
  • Acid-induced pain and its modulation in humans
    Jones, NG; Slater, R; Cadiou, H
  • Epidemiology of rheumatic diseases
    Sangha, O
  • Epidemiology and burden of osteoarthritis
    Litwic, A; Edwards, MH; Dennison, EM; Cooper, C
  • Estimates of the prevalence of arthritis and other rheumatic conditions in the United States
    Lawrence, RC; Felson, DT; Helmick, CG; Arnold, LM; Choi, H; Deyo, RA
  • Pain in osteoarthritis: assessment and impact on the disability
    Salaffi, F
  • Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls
    Salaffi, F; Carotti, M; Stancati, A; Grassi, W
  • Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment
    Mease, PJ; Hanna, S; Frakes, EP; Altman, RD
  • Arthritis and pain. Future targets to control osteoarthritis pain
    Dray, A; Read, SJ
  • Pathophysiology and treatment of pain in joint disease
    Schaible, HG; Schmelz, M; Tegeder, I
  • The sources of pain in osteoarthritis: a pathophysiological review
    Salaffi, F; Ciapetti, A; Carotti, M
  • Mechanisms of pain in arthritis
    Schaible, HG; Ebersberger, A; von Banchet, GS
  • Osteoarthritis, angiogenesis and inflammation
    Bonnet, CS; Walsh, DA
  • Primary care treatment of knee pain—a survey in older adults
    Porcheret, M; Jordan, K; Jinks, C; Croft, P
  • Osteoarthritis: rational approach to treating the individual
    Juni, P; Reichenbach, S; Dieppe, P
  • Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis
    Gore, M; Sadosky, A; Leslie, D; Tai, KS; Seleznick, M
  • OARSI guidelines for the non-surgical management of knee osteoarthritis
    McAlindon, TE; Bannuru, RR; Sullivan, MC
  • Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials
    Bjordal, JM; Klovning, A; Ljunggren, AE; Slordal, L
  • Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
    Chen, YF; Jobanputra, P; Barton, P
  • Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis
    Costa, BR; Reichenbach, S; Keller, N; Nartey, L; Wandel, S; Jüni, P; Trelle, S
  • Relative benefit–risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis
    Walsem, A; Pandhi, S; Nixon, RM; Guyot, P; Karabis, A; Moore, RA
  • Central sensitization: a generator of pain hypersensitivity by central neural plasticity
    Latremoliere, A; Woolf, CJ
  • The cortical representation of pain
    Treede, RD; Kenshalo, DR; Gracely, RH; Jones, AK
  • Central pain mechanism in the rheumatic diseases
    Phillips, K; Clauw, DJ
  • Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain
    Burian, M; Tegeder, I; Seegel, M; Geisslinger, G
  • Effects of NSAIDs and paracetamol (acetaminophen) on protein kinase C epsilon translocation and on substance P synthesis and release in cultured sensory neurons
    Vellani, V; Franchi, S; Prandini, M; Moretti, S; Castelli, M; Giacomoni, C; Sacerdote, P
  • Pain in the rheumatic diseases. Investigation of a key health status component
    Kazis, LE; Meenan, RF; Anderson, JJ
  • Pain in systemic inflammatory rheumatic diseases
    Atzeni, F; Masala, IF; Salaffi, F; Franco, M; Casale, R; Sarzi-Puttini, P
  • Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis
    Odegard, S; Finset, A; Mowinckel, P; Kvien, TK; Uhlig, T
  • Rheumatoid arthritis: why wait? Explaining delays in seeking therapy for early arthritis
    Atzeni, F; Sarzi-Puttini, P
  • Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years
    Andersson, ML; Svensson, B; Bergman, S
  • Chronic widespread pain in the spectrum of rheumatological diseases
    Atzeni, F; Cazzola, M; Benucci, M; Franco, M; Salaffi, F; Sarzi-Puttini, P
  • Central sensitization: implications for the diagnosis and treatment of pain
    Woolf, CJ
  • Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis
    Raychaudhuri, SP; Raychaudhuri, SK; Atkuri, KR; Herzenberg, LA; Herzenberg, LA
  • The role of proinflammatory cytokines in the generation and maintenance of joint pain
    Schaible, HG; Banchet, GS; Boettger, MK
  • Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis
    Sarzi-Puttini, P; Atzeni, F; Lanata, L; Bagnasco, M
  • Randomized comparison of combined step-down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M; Verhoeven, AC; Markusse, HM
  • Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
    Emery, P
  • Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e initiative
    Whittle, SL; Colebatch, AN; Buchbinder, R
  • Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience
    Joshi, S; Rapoport, AM
  • Skin penetration and tissue permeation after topical administration of diclofenac
    Hagen, M; Baker, M
  • Analgesic use and the risk for progression of chronic kidney disease
    Kuo, HW; Tsai, SS; Tiao, MM; Liu, YC; Lee, IM; Yang, CY
  • Use of non-selective non-steroidal anti-inflammatory drugs in relation to cardiovascular events. A systematic pharmacoepidemiological review
    Kontogiorgis, C; Valikeserlis, I; Hadjipavlou-Litina, D; Nena, E; Constantinidis, TC
  • Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
    Warner, TD; Giuliano, F; Vojnovic, I; Bukasa, A; Mitchell, JA; Vane, JR
  • Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents
    Laporte, JR; Ibanez, L; Vidal, X; Vendrell, L; Leone, R
  • Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology
    Altman, R; Bosch, B; Brune, K; Patrignani, P; Young, C
  • Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study
    Zerbini, C; Ozturk, ZE; Grifka, J; Maini, M; Nilganuwong, S; Morales, R
  • Central Sensitization and Altered Central Pain Processing in Chronic Low Back Pain
    Roussel, Nathalie A.; Nijs, Jo; Meeus, Mira; Mylius, Veit; Fayt, Cécile; Oostendorp, Rob
  • Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent
    Pantziarka, P; Sukhatme, V; Bouche, G; Meheus, L; Sukhatme, VP
  • The importance of treating the field in actinic keratosis
    Stockfleth, E
  • Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis
    Maltusch, A; Röwert-Huber, J; Matthies, C; Lange-Asschenfeldt, S; Stockfleth, E
  • Novel antitumor platinum(II) conjugates containing the nonsteroidal anti-inflammatory agent diclofenac: synthesis and dual mechanisms of antiproliferative effects
    Intini, FP; Zajac, J; Novohradsky, V; Saltarella, T; Pacifico, C; Brabec, V; Natile, G; Kasparkova, J